Vaccine News

Vaccine news brought to you by Precision Vaccinations.

Jun 9, 2023 • 10:29 am CDT
ECDC dengue map May 2023

Filomeno Fortes, the Director of Portugal's Institute of Hygiene and Tropical Medicine, recently gave an interview on the importance of Takeda's QDENGA® vaccine against dengue, made available in Portugal in May 2023.

"The vaccine brings some innovation to the prevention of a disease that is considered by the World Health Organization (WHO) as one of the ten global threats to world health," commented Fortes.

Initially authorized in Indonesia in August 2022, QDENGA had been authorized as of June 9, 2023, in Argentina, Brazil, Europe, and the U.K.

In the U.S., the FDA is considering the authorization of QDENGA.

Since most dengue cases in the U.S. are travel-related, additional QDENGA authorization should reduce the incidence of this disease.

About 4 billion people live in areas with a risk of dengue.

For example, the Florida Health Department recently reported three additional travel-associated dengue cases, which increases the 2023 total to 80 patients.

In 2022, 903 travel-associated and 68 locally-acquired dengue cases were reported in Florida.

Dengue viruses are spread to people through the bite of an infected Aedes species mosquito, says the U.S. CDC. Dengue is often a leading cause of illness in at-risk areas.

Jun 9, 2023 • 8:05 am CDT
by Cheryl Holt

The U.S. Centers for Disease Control and Prevention (CDC) today published a Morbidity and Mortality Weekly Report that confirmed children and infants have been infected with the mpox virus.

From May 17 to December 31, 2022, the CDC reported that 45 children aged ≤12 years were diagnosed with mpox.

And three were less than one week old. These infants likely had perinatal exposures.

The vaccination status (JYNNEOS®) of these children was not disclosed.

The CDC stated on June 9, 2023, when caring for a child with mpox, direct contact with the child’s rash should be avoided, and gloves should be worn. In addition, postexposure prophylaxis (TPOXX®) should be considered for all household members.

On May 18, 2023, the CDC confirmed TPOXX might be used for non-variola orthopoxvirus infection (e.g., mpox) under a CDC-held Expanded Access Investigational New Drug Protocol for children weighing at least 3 kg.

However, mpox postexposure prophylaxis efficacy is unstudied.

Additional mpox research was updated in June 2023.

Jun 9, 2023 • 5:59 am CDT
by Gerd Altmann

WestVac Biopharma and West China Medical Center, Sichuan University, today announced Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 Trivalent (XBB.1.5+BA.5+Delta) Protein Vaccine (Sf9 cell) was authorized by relevant authorities in China.

As of June 8, 2023, this is the first COVID-19 vaccine in the world authorized against XBB descendent lineages of the beta coronavirus SARS-CoV-2. 

WestVac leveraged the rapid response of the insect cell expression platform in constructing the vector for Coviccine, which is of high purity and high quality for human use.

The subunit vaccine antigen is designed based on the structure of the targeting S-RBD and HR proteins of the COVID-19 subvariants XBB.1.5 and BA.5 and self-assembled into stable trimeric protein particles with squalene-based oil-in-water emulsion adjuvant added after purification and mixing.

This novel adjuvant significantly raises the titer of neutralizing antibodies, enabling the trimeric protein vaccine to induce a higher T-cell immune response.

Recent studies have shown that Coviccine induced a high titer of neutralizing antibodies against multiple subvariants.

Previously, the WHO Technical Advisory Group on COVID-19 Vaccine Composition advised on May 18, 2023, that new formulations of COVID-19 vaccines should aim to induce antibody responses that neutralize XBB descendent lineages.

As of the end of May 2023, the XBB family of variants accounted for about 90% of infections in China.

And in the U.S., over 90% of all variants are from the XBB family.

Jun 8, 2023 • 2:58 pm CDT
by Jess Foami

CNBC reported today the U.S. FDA's Antimicrobial Drugs Advisory Committee voted 21-0 to recommend full approval for Beyfortus® (Nirsevimab) for infants and young children.

The FDA considers committee recommendations when finalizing its decisions.

Beyfortu has already been approved in Canada, Europe, and the United Kingdom.

Beyfortus is the first extended half-life monoclonal antibody offering passive immunization to prevent lower respiratory tract infections caused by the respiratory syncytial virus (RSV). 

AstraZeneca and Sanofi developed this RSV therapy.

This antibody therapy is not an RSV vaccine. The FDA recently approved two RSV vaccines for seniors.

Jun 8, 2023 • 12:30 pm CDT
from Pixabay

The U.S. CDC's Morbidity and Mortality Weekly Report published today indicates about 66% of mpox vaccine–eligible persons remained unvaccinated.

From May 2022–April 2023, a total of 748,329 first JYNNEOS® (MVA-BN) vaccine doses (of the two recommended) were administered in the United States.

During the initial months of the outbreak, lower vaccination coverage rates among racial and ethnic minority groups were reported.

Focusing on the racial and ethnic groups with more significant mpox vaccination shortfalls, prioritizing resources, and improving access to vaccination for these groups can reduce the overall shortfall in mpox vaccination while promoting health equity.

However, after the implementation of initiatives developed to expand access to mpox vaccination, coverage among racial and ethnic minority groups increased, stated the CDC on June 9, 2023.

Jun 8, 2023 • 11:33 am CDT
WHO Weekly epidemiological update on COVID-19 - June 8, 2023

The World Health Organization (WHO) today reported over 10,000 fatalities related to COVID-19 were reported in the last 28 days, a decrease of 47% compared to April 10 to May 7, 2023.

During this 28-day reporting period, 144 of 243 (59%) countries and territories reported at least one COVID-19 case.

The situation at the regional level shows decreases in COVID-19 cases and fatalities in all six WHO regions. 

Recently, the WHO and other authorities have announced their recommendations for updated COVID-19 vaccines for late 2023.

And the Forest plots displaying the effectiveness of COVID-19 vaccines against the Omicron variants are available on View-hub.org

Jun 8, 2023 • 9:45 am CDT
U.S. CDC travel alert - Marburg outbreak - June 2023

The outbreak of Marburg Virus Disease in Equatorial Guinea ended today with no new cases reported over the past 42 days after the last patient was discharged from treatment.

The outbreak, declared on February 13, was the first in Equatorial Guinea.

A total of 17 laboratory-confirmed cases and 12 deaths were recorded.

Five districts in four of Equatorial Guinea’s eight provinces were affected.

The western Litoral province Bata district was worst-hit, with 11 laboratory-confirmed cases reported. Among the reported cases, many were closely linked either through social gatherings and networks or geographically.

“While outbreak-prone diseases continue to pose a major health threat in Africa, we can bank on the region’s growing expertise in health emergency response to act quickly and decisively to safeguard the health and avert widespread loss of life,” said Dr. Matshidiso Moeti, World Health Organization (WHO) Regional Director for Africa, in a press release on June 8, 2023.

“The hard work by Equatorial Guinea’s health workers and support by partner organizations has been crucial in ending this outbreak. WHO continues to work with countries to improve measures to detect and respond effectively to disease outbreaks,” Dr Moeti added.

To support Equatorial Guinea’s response to the just-ended outbreak, WHO deployed experts in epidemiology, clinical management, health operations, logistics, risk communications, and infection prevention and control.

The Organization worked with the health authorities to set up a treatment center, provided medical supplies, including antivirals, and trained health workers in the critical aspects of outbreak control.

The WHO also supported the efforts by the authorities in neighboring Cameroon and Gabon to ramp up outbreak readiness and response.

Although the outbreak has ended, WHO continues to work with Equatorial Guinea to maintain measures such as surveillance and testing to enable prompt action should flare-ups of the virus occur, with the training provided during the outbreak helping to strengthen readiness capacity.

Marburg is in the same family as the virus that causes Ebola Virus Disease.

The Marburg virus is transmitted to people from fruit bats and spreads among humans through direct contact with the bodily fluids of infected people, surfaces, and materials.

In Africa, the first outbreak of Marburg was recorded in South Africa in 1975, followed by two others in Kenya in the 1980s. Since then, outbreaks have been reported in Angola, the Democratic Republic of the Congo, Ghana, Guinea, Uganda, and most recently, Equatorial Guinea and Tanzania.

Jun 8, 2023 • 5:34 am CDT
U.S. Embassy Denmark June 2023

The U.S. Department of State today reissued its Level 2, Exercise Increased Caution travel alert for the Kingdom of Denmark.

This alert stated civil unrest events may occur at tourist locations, transportation hubs, markets/shopping malls, local government facilities, hotels, clubs, restaurants, places of worship, parks, major sporting and cultural events, educational institutions, airports, and other public areas at any time.

Furthermore, the U.S. Mission in Copenhagen issued a Demonstration Alert on June 7, 2023, reminding U.S. citizens to remain vigilant if in the area of demonstrations as these events can be unpredictable and quickly turn violent.

If you decide to travel to the Kingdom of Denmark, enroll in the Smart Traveler Program to receive local Alerts in an emergency.

From a health perspective, the U.S. CDC recently suggested prospective visitors confirm their immunization status with a healthcare provider before visiting Demark.

Jun 7, 2023 • 4:35 pm CDT
Mammals infected with HAPI viruses June 2023

The USDA Animal and Plant Health Inspection Service (APHIS) recently announced it added Gabon, Guinea, and Moldova to the list of regions considered to be affected by highly pathogenic avian influenza (HPAI), known as bird flu.

Bird flu outbreaks are mainly located in areas of the Pacific Flyway. 

The HAPI updates were confirmed on May 23, 2023.

On May 23, 2022, after confirming that the HPAI occurred in commercial birds or poultry, APHIS added Gabon to the regions where HPAI exists.

On June 3, 2022, the veterinary authorities of Guinea reported to WOAH an HPAI occurrence in that country.

On January 24, 2022, the veterinary authorities of Moldova reported to WOAH an HPAI occurrence in that country.

In the U.S., the Department of Agriculture's Animal and Plant Health Inspection Service reported the Eurasian (H5 clade 2.3.4.4b.) appeared in North America in January 2022 and has impacted over 58 million birds in 47 states as of June 2023.

Bird flu infections have also been detected in various mammals, such as bears, cats, dogs, dolphins, ferrets, foxes, minks, sea lions, and skunks.

As of June 7, 2023, bird flu vaccines are available for people, and vaccine candidates are being tested for birds.

Jun 7, 2023 • 3:56 pm CDT
EMA June 7, 2023

The European Centre for Disease Prevention and Control (ECDC) and the European Medicines Agency (EMA) today issued a joint statement on adapted COVID-19 vaccines and considerations for their use during the upcoming 2023 vaccination campaigns.

In line with the outcome of meetings of international regulators and the World Health Organization (WHO) in May 2023, the EMA’s Emergency Task Force recommended on June 6, 2023, updating COVID-19 vaccines to target XBB strains (a subgroup of the SARS-CoV-2 Omicron strain), which have become dominant in Europe.

The EMA and ECDC also noted that monovalent vaccines (targeting only one strain) are a reasonable choice to protect people against dominant and emerging coronavirus strains.

Other COVID-19 vaccine news is posted by Precision Vaccinations.

Jun 7, 2023 • 2:59 pm CDT
by Gerd Altmann

Considering the increase of respiratory viruses activity in the Andean sub-region and Southern cone, the Pan American Health Organization / World Health Organization (PAHO/WHO) today recommended Member States strengthen and integrate surveillance for influenza, respiratory syncytial virus (RSV), and SARS-CoV-2.

And the PAHO suggested, on June 6, 2023, adopting the necessary measures for preventing and controlling severe outcomes, including ensuring high vaccination coverage in high-risk groups such as children.

In the Southern sub-region, influenza activity has shown a marked increase with high circulation levels. Influenza A viruses have predominated during the last four epidemiological weeks (EW).

And RSV activity has shown a pronounced rise and is currently at medium circulation levels in the past EW.

SARS-CoV-2 activity has remained at low levels. 

As the Southern Hemisphere's 2023-2024 influenza season accelerates, various flu shots are available for most people over six months.

And for infants, the RSV monoclonal antibody palivizumab should be administered during the first year of life to infants with hemodynamically significant heart disease or chronic lung disease of prematurity (<32 weeks gestation who require >21% O2 for the first 28 days of life).

Jun 7, 2023 • 6:13 am CDT
Celebrity Cruises Summit June 2023

The U.S. Centers for Disease Control and Prevention (CDC) recently reported 152 of 2,144 (7.09%) people were sickened with norovirus during the Celebrity Cruises Summit cruise to Bermuda between May 15–May 25, 2023.

Twenty-five crew members also reported being ill during the voyage.

Norovirus is a very contagious virus that causes vomiting and diarrhea. Anyone can get infected and sick with norovirus, says the CDC.

As of May 31, 2023, Celebrity Cruises reported the following actions:

  • Increased cleaning and disinfection procedures according to the ship’s outbreak prevention and response plan.
  • Notified current guests of the situation onboard and encouraged illness reporting and good hand hygiene.
  • Collected and sent stool specimens from gastrointestinal illness cases to the CDC laboratory.
  • Provided twice daily reports of gastrointestinal illness cases to VSP during the outbreak investigation.
  • Consulted with VSP about sanitation cleaning procedures and reporting ill cases.
  • Notified embarking guests of the situation onboard and encouraged illness reporting and good hand hygiene.

Throughout 2023, the CDC has reported ten other norovirus outbreaks on cruise ships.

As of June 7, 2023, there are norovirus vaccine candidates conducting clinical studies.

Jun 7, 2023 • 5:48 am CDT
by Dean Moriarty

GSK plc today announced that the European Commission had authorized Arexvy™ for active immunization to prevent lower respiratory tract disease (LRTD) caused by a respiratory syncytial virus (RSV) in adults 60 and older.

The first launches are planned for the 2023/2024 RSV season, which typically starts in the autumn.

Tony Wood, Chief Scientific Officer, GSK, commented in a press release on June 7, 2023, "This authorization for Arexvy means eligible adults can be vaccinated against RSV disease for the first time, reinforcing GSK's long history of vaccine innovation."

Our strong manufacturing capability and scale, including from our vaccine manufacturing site in Belgium, means we are ready to deliver the (RSV) vaccine as countries begin to launch."

RSV is a common, contagious respiratory virus that leads to over 270,000 hospitalizations and approximately 20,000 in-hospital deaths each year in adults aged 60 years and over in Europe.

Those with underlying medical conditions, such as diabetes and chronic heart and lung disease, drive the majority of RSV hospitalizations.

In the U.S., two RSV vaccines have been authorized for seniors, and one RSV monoclonal antibody (Beyfortus®) is seeking authorization for infants/children.

Jun 6, 2023 • 5:52 pm CDT
State Dept map June 6, 2023

The U.S. Department of State today reissued Level 2: Exercise Increased Caution travel advisories for two additional South American countries, the Plurinational State of Bolivia and the Republic of Ecuador.

On June 6, 2023, the State Department confirmed both countries are confronting civil unrest.

Previously, on June 1, 2023, the State Department issued a similar advisory for Peru.

If you decide to visit these countries, monitor local media for breaking events, avoid demonstrations, and be prepared to adjust your plans, says the U.S. government.

And prepare a contingency plan for emergencies and enroll in the Smart Traveler Program to be located in a crisis.

From a health perspective, the U.S. CDC suggests speaking with a travel vaccine provider about one month before visiting these countries to review immunization and medication options targeting diseases such as dengue and yellow fever.

 

Jun 6, 2023 • 3:30 pm CDT
Florida RSV Review June 3, 2023

The Florida Department of Health published an updated Respiratory Syncytial Virus (RSV) weekly report that indicates an increased positivity rate but no outbreaks as of June 3, 2023.

This is positive news since Florida’s RSV season is traditionally more extended than the rest of the U.S. 

During the summer of 2021, Florida reported an unseasonably high number of RSV outbreaks, but activity during the 2021-22 season returned to a more typical trend.

From a global perspective, the World Health Organization Influenza Update N° 446, published on May 29, 2023, disclosed RSV activity was generally low except in Australia and a few countries in the Region of the Americas. 

And RSV has increased in several countries in tropical and temperate South America.

Furthermore, the U.S. is better prepared for the 2023-2024 RSV season than ever.

As of June 6, 2023, there are two approved RSV vaccines and several candidates conducting late-stage studies.